CONSORTIUM FOR ANTIMALARIAL DEVELOPMENT
抗疟开发联盟
基本信息
- 批准号:7348998
- 负责人:
- 金额:$ 3.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-05-01 至 2007-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. We developed a rhesus monkey model to examine the effects of malaria (Plasmodium coatneyi) during pregnancy. This project, supported by an NIH R01, explores maternal immunologic responses, the effects of gravidity, and preexisting immunity on the severity of clinical malaria and fetal outcome. The FACS analysis and per diem for the infants is supported by a subcontract through Mississippi state university and the CDC. The terms ¿low birth weight¿ (LBW) and ¿small for gestational age¿ (SGA) describe infants born prematurely and/or with intrauterine growth retardation (IUGR), but do not define the nature of the problem. The monkey model shows that there are complex indicators of poor infant outcome and weight alone is not sufficient as the sole determinant. Human studies show that malaria, not prematurity, leads to IUGR but this has been based on birth weight with clinical assessment of gestational age, not on ultrasonography. Utilizing ultrasonography, we demonstrated skeletal abnormalities (dysregulated osteogenesis) including small head measurments and femur length indicative of symmetric IUGR (SIUGR), as well as abnormal elliptical shaped heads with increased head length :head width ratios. Asymmetric IUGR (AIUGR) or reduced body fat deposition was also identified. After birth the infants continued to be measured and monthly FACs analysis was performed. Malaria was associated not only with impaired fetal growth but impaired infant growth and persistent immunologic alterations. Infants displayed malaria-induced modulation of their immune systems, whereby both humoral (B-lymphocytes) and cellular (T-lymphocyte) development was affected. In utero exposure to malaria or malaria antigens are likely responsible. Infants displayed increased susceptibility to a variety of microbial agents. Our findings indicate that the model is relevant for the examination ¿fetal programming¿ a hypothesis which states that the origins of adult disease are related to the fetal environment in utero.
该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者(PI)可能从另一个NIH来源获得主要资金,因此可以在其他CRISP条目中表示。所列机构为中心,不一定是研究者所在机构。我们开发了一个恒河猴模型,以检查疟疾(疟原虫coatneyi)在怀孕期间的影响。该项目由NIH R 01支持,探讨了母体免疫反应、妊娠的影响以及预先存在的免疫对临床疟疾严重程度和胎儿结局的影响。通过密西西比州立大学和疾病预防控制中心的一项研究,婴儿的流式细胞仪分析和每日津贴得到了支持。 条款?低出生体重(LBW)和小于胎龄儿(SGA)描述了早产儿和/或宫内生长迟缓(IUGR),但没有定义问题的性质。猴子模型表明,婴儿结局不佳的指标很复杂,体重本身不足以作为唯一的决定因素。人类研究表明,疟疾,而不是早产,导致IUGR,但这是基于出生体重与临床评估胎龄,而不是超声检查。利用超声检查,我们证明了骨骼异常(成骨失调),包括小的头部测量和股骨长度指示对称IUGR(SIUGR),以及异常椭圆形的头部与头部长度:头部宽度比增加。还发现了不对称IUGR(AIUGR)或体脂沉积减少。出生后,继续测量婴儿,并每月进行FACs分析。 疟疾不仅与胎儿生长受损有关,还与婴儿生长受损和持续的免疫学改变有关。婴儿表现出疟疾引起的免疫系统调节,体液(B淋巴细胞)和细胞(T淋巴细胞)的发育受到影响。子宫内接触疟疾或疟疾抗原可能是原因。婴儿对各种微生物的易感性增加。我们的研究结果表明,该模型与检查胎儿编程有关,这是一种假设,认为成人疾病的起源与子宫内的胎儿环境有关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BILLIE B DAVISON其他文献
BILLIE B DAVISON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BILLIE B DAVISON', 18)}}的其他基金
MALARIA IMMUNOLOGY AND GENETICS IN THE AMAZON (MIGIA) PROJECT
亚马逊 (MIGIA) 项目中的疟疾免疫学和遗传学
- 批准号:
7349085 - 财政年份:2006
- 资助金额:
$ 3.1万 - 项目类别:
PROMPT TREATMENT OF PARASITEMIA DURING PREGNANCY LIMITS PLACENTAL PATHOLOGY
妊娠期间及时治疗寄生虫血症可限制胎盘病理学
- 批准号:
7165091 - 财政年份:2005
- 资助金额:
$ 3.1万 - 项目类别:
CELLULAR RESPONSES ASSOCIATED WITH MALARIA IN PREGNANCY
与妊娠期疟疾相关的细胞反应
- 批准号:
6970762 - 财政年份:2004
- 资助金额:
$ 3.1万 - 项目类别:
相似海外基金
Targeting epigenetics for antimalarial development
针对抗疟疾开发的表观遗传学
- 批准号:
2876747 - 财政年份:2023
- 资助金额:
$ 3.1万 - 项目类别:
Studentship
Development of a New Class of Broad-Stage Antimalarial Agents
新型多阶段抗疟药物的开发
- 批准号:
nhmrc : 2000087 - 财政年份:2021
- 资助金额:
$ 3.1万 - 项目类别:
Development Grants
Development of new antimalarial trandermal agent
新型抗疟透皮剂的研制
- 批准号:
18K07086 - 财政年份:2018
- 资助金额:
$ 3.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Structural Analysis of Non Mevalonate Pathway Enzyme Groups aiming at Development of Novel Antimalarial Drugs
旨在开发新型抗疟药物的非甲羟戊酸途径酶群的结构分析
- 批准号:
15K19086 - 财政年份:2015
- 资助金额:
$ 3.1万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Development of antimalarial histone deacetylase inhibitors
抗疟组蛋白脱乙酰酶抑制剂的开发
- 批准号:
nhmrc : GNT1093378 - 财政年份:2015
- 资助金额:
$ 3.1万 - 项目类别:
Development Grants
Development of antimalarial histone deacetylase inhibitors
抗疟组蛋白脱乙酰酶抑制剂的开发
- 批准号:
nhmrc : 1093378 - 财政年份:2015
- 资助金额:
$ 3.1万 - 项目类别:
Development Grants
Development of Antimalarial Drug Leads Through Inhibition of Food Vacuole Falcipains
通过抑制食物泡镰刀菌蛋白酶来开发抗疟药物
- 批准号:
nhmrc : 1062216 - 财政年份:2014
- 资助金额:
$ 3.1万 - 项目类别:
Project Grants
Targeting the Plasmodium falciparum Metalloaminopeptidases for Development of New Antimalarial Agents
针对恶性疟原虫金属氨基肽酶开发新型抗疟药物
- 批准号:
nhmrc : 1063786 - 财政年份:2014
- 资助金额:
$ 3.1万 - 项目类别:
Project Grants
Development of antimalarial drugs targeting the membrane trafficking
开发针对膜运输的抗疟药物
- 批准号:
26670201 - 财政年份:2014
- 资助金额:
$ 3.1万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of antimalarial agents through a design of reversely binding protease inhibitors
通过反向结合蛋白酶抑制剂的设计开发抗疟药物
- 批准号:
25460163 - 财政年份:2013
- 资助金额:
$ 3.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




